HEPATITIS-B - GLOBAL IMPORTANCE AND NEED FOR CONTROL

被引:206
作者
MAYNARD, JE [1 ]
机构
[1] PROGRAM APPROPRIATE TECHNOL HLTH, SEATTLE, WA 98109 USA
关键词
cost-effectiveness; Expanded Programmed on Immunization; Hepatitis B; plasma-derived; recombinant;
D O I
10.1016/0264-410X(90)90209-5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Hepatitis B is a disease of global importance, with > 300 million carriers of the virus world-wide. Hepatitis B virus (HBV) is the cause of up to 80% of cases of primary liver cancer, the singel most important cause of mortality globally. In countries where HBV carrier rates reach 10% HBV infection may account for 3% of total mortality, a level which exceeds polio-related mortality before the introduction of polio vaccine. The only means by which hepatitis B can be eventually eliminated is mas vacciniation of infants with hepatitis B vaccine as part of the Expanded Programme on Immunization (EPI) in areas of the world where the HBV carrier rate exceeds 2.5%. With recent dramatic increases in hepatitis B vaccine production and decreases in per-dpse price, there are grounds for optimism that global HBV infection rates may be reduced by as much as 90% over the next 10 years. © 1990.
引用
收藏
页码:S18 / S20
页数:3
相关论文
共 5 条
  • [1] Beasley R.P., 1984, VIRAL HEPATITIS LIVE, P209
  • [2] MAYNARD JE, 1989, REV INFECT DIS, V11, pS574
  • [3] Maynard JE, 1988, VIRAL HEPATITIS LIVE, P967
  • [4] 1988, B WORLD HEALTH ORGAN, V66, P443
  • [5] 1983, WHO TECH REP SER, V691, P8